Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 30, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, March 30, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
March 28, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, March 28, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD will present at...
Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
March 16, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, March 16, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD, will present...
Paratek Pharmaceuticals to Present at the 38th Annual Cowen & Co. Health Care Conference
March 02, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, March 02, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD, will present...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 01, 2018 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, March 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019
March 01, 2018 07:00 ET
|
Paratek Pharmaceuticals
Completed submission of NDAs for oral and intravenous omadacycline for the treatment of pneumonia and skin infectionsExpanded medical affairs and payer account management teams in readiness for...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
February 15, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
February 05, 2018 07:30 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that on February 2, 2018, it completed the submission of two New Drug Applications (NDAs) to the...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 01, 2018 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference
January 31, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), announced today that its President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD and Chief...